Literature DB >> 15867390

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.

Gauri J Sabnis1, Danijela Jelovac, Brian Long, Angela Brodie.   

Abstract

To study the long-term effects of estrogen deprivation on breast cancer, MCF-7Ca human estrogen receptor-positive breast cancer cells stably transfected with human aromatase gene were cultured in the steroid-depleted medium for 6 to 8 months until they had acquired the ability to grow. Proliferation of these cells (UMB-1Ca) was accompanied by increased expression of human epidermal growth factor receptor 2, increased activation of AKT through phosphorylation at Ser473 and Thr308, and increased invasion compared with parental MCF-7Ca cells. Estrogen receptor expression was also increased 5-fold. Although growth was inhibited by the antiestrogen fulvestrant, the IC50 was 100-fold higher than for parental MCF-7Ca cells. Aromatase inhibitor letrozole also inhibited growth at 10,000-fold higher concentration than required for MCF-7Ca cells, whereas anastrozole, exemestane, formestane, and tamoxifen were ineffective at 100 nmol/L. Growth of UMB-1Ca cells was inhibited by phosphatidylinositol 3-kinase inhibitor wortmannin (IC50 approximately 25 nmol/L) and epidermal growth factor receptor kinase inhibitor gefitinib (ZD 1839; IC50 approximately 10 micromol/L) whereas parental MCF-7Ca cells were insensitive to these agents. Concomitant treatment of UMB-1Ca cells with the signal transduction inhibitors and anastrozole and tamoxifen restored their growth inhibitory effects. These studies show that estrogen deprivation results in up-regulation of growth factor signaling pathways, which leads to a more aggressive and hormone refractory phenotype. Cross-talk between ER and growth factor signaling was evident as inhibition of these pathways could restore estrogen responsiveness to these cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867390     DOI: 10.1158/0008-5472.CAN-04-4092

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

2.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Authors:  C Giordano; S Catalano; S Panza; D Vizza; I Barone; D Bonofiglio; L Gelsomino; P Rizza; S A W Fuqua; S Andò
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

Review 3.  Natural products as aromatase inhibitors.

Authors:  Marcy J Balunas; Bin Su; Robert W Brueggemeier; A Douglas Kinghorn
Journal:  Anticancer Agents Med Chem       Date:  2008-08       Impact factor: 2.505

Review 4.  Optimizing the use of neoadjuvant endocrine therapy.

Authors:  Laila S Agrawal; Ingrid A Mayer
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

Review 5.  The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-08       Impact factor: 4.292

Review 6.  What do we know about the mechanisms of aromatase inhibitor resistance?

Authors:  Shiuan Chen; Selma Masri; Xin Wang; Sheryl Phung; Yate-Ching Yuan; Xiwei Wu
Journal:  J Steroid Biochem Mol Biol       Date:  2006-10-19       Impact factor: 4.292

7.  Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.

Authors:  Gauri Sabnis; Olga Goloubeva; Rabia Gilani; Luciana Macedo; Angela Brodie
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  Calmodulin modulates Akt activity in human breast cancer cell lines.

Authors:  Christine M Coticchia; Chetana M Revankar; Tushar B Deb; Robert B Dickson; Michael D Johnson
Journal:  Breast Cancer Res Treat       Date:  2008-06-28       Impact factor: 4.872

9.  Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  Cancer Res       Date:  2009-10-27       Impact factor: 12.701

10.  Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.

Authors:  I Barone; D Iacopetta; K R Covington; Y Cui; A Tsimelzon; A Beyer; S Andò; S A W Fuqua
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.